The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberrationThe beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration
|
0 Comment|
Regardless of current advances within the systemic therapy of metastatic gastric most cancers (GC), prognostic outcomes stay poor. Appreciable analysis effort has been invested in characterizing the genomic panorama of
